Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Medical Developments International Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Medical Developments International kazanç ve gelirin sırasıyla yıllık 93.1% ve 14.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 94.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7% olacağı tahmin edilmektedir.

Anahtar bilgiler

93.1%

Kazanç büyüme oranı

94.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	54.9%
Gelir büyüme oranı	14.4%
Gelecekteki özkaynak getirisi	7.0%
Analist kapsamı	Low
Son güncelleme	26 Aug 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

May 13

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

May 03

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Mar 11

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Jan 16

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Jan 03

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Aug 09

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

Apr 24

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Jul 04

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Mar 04

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Mar 05

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

Feb 07

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Dec 16

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Dec 10

Kazanç ve Gelir Büyüme Tahminleri

ASX:MVP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	55	4	4	7	1
6/30/2026	48	0	5	7	1
6/30/2025	41	-4	1	3	1
6/30/2024	33	-41	-14	-11	N/A
3/31/2024	33	-30	-17	-12	N/A
12/31/2023	34	-19	-21	-15	N/A
9/30/2023	33	-12	-23	-16	N/A
6/30/2023	32	-6	-24	-16	N/A
3/31/2023	29	-4	-22	-16	N/A
12/31/2022	26	-2	-20	-15	N/A
9/30/2022	24	-7	-18	-13	N/A
6/30/2022	22	-12	-16	-11	N/A
3/31/2022	22	-16	-17	-10	N/A
12/31/2021	22	-19	-17	-10	N/A
9/30/2021	24	-16	-16	-9	N/A
6/30/2021	25	-13	-15	-9	N/A
3/31/2021	25	-7	-14	-8	N/A
12/31/2020	24	-1	-13	-6	N/A
9/30/2020	23	0	-11	-3	N/A
6/30/2020	23	0	-9	0	N/A
3/31/2020	22	1	-8	1	N/A
12/31/2019	22	1	-8	1	N/A
9/30/2019	22	1	2	11	N/A
6/30/2019	21	1	11	21	N/A
3/31/2019	20	1	12	22	N/A
12/31/2018	19	0	12	23	N/A
9/30/2018	18	0	2	12	N/A
6/30/2018	17	0	-9	2	N/A
3/31/2018	18	1	N/A	2	N/A
12/31/2017	18	2	N/A	3	N/A
9/30/2017	18	2	N/A	3	N/A
6/30/2017	18	2	N/A	4	N/A
3/31/2017	18	2	N/A	4	N/A
12/31/2016	18	2	N/A	4	N/A
9/30/2016	17	2	N/A	8	N/A
6/30/2016	15	2	N/A	12	N/A
3/31/2016	14	1	N/A	12	N/A
12/31/2015	12	1	N/A	13	N/A
9/30/2015	12	1	N/A	8	N/A
6/30/2015	12	2	N/A	3	N/A
3/31/2015	11	1	N/A	3	N/A
12/31/2014	10	1	N/A	3	N/A
9/30/2014	10	1	N/A	2	N/A
6/30/2014	9	1	N/A	1	N/A
3/31/2014	10	1	N/A	1	N/A
12/31/2013	10	1	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MVP önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.4% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: MVP önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: MVP önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: MVP şirketinin gelirinin (yıllık 14.4% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MVP şirketinin gelirinin (yıllık 14.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MVP 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7 %).

Medical Developments International Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to AU$0.033 loss

Price target increased by 38% to AU$3.03

Price target decreased by 29% to AU$1.60

Price target decreased to AU$4.30

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Consensus forecasts updated

Recent updates

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Consensus EPS estimates upgraded to AU$0.033 loss

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024

Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump

Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?

Price target increased by 38% to AU$3.03

New minor risk - Profitability

Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward

Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Price target decreased by 29% to AU$1.60

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

New minor risk - Financial data availability

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Price target decreased to AU$4.30

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Price target decreased to AU$6.18

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates

Analysts lower EPS estimates to -AU$0.037

Revenue and earnings miss expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns

New 90-day high: AU$7.18

Price target raised to AU$7.25

Analysts lower EPS estimates to -AU$0.018

Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)

Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.61

Price target lowered to AU$6.97

Analysts lower EPS estimates to -AU$0.022

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Analysts update estimates

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.29

New 90-day low - AU$5.76